Meta-analysis Ranks Clomipramine High in OCD

November 14, 2026by Chris Aiken, MD0
The oldest OCD drug still works best. Can patients tolerate it

STUDY: Cohen S et al, Lancet Psychiatry 2026

STUDY TYPE: Network meta-analysis

FUNDING: Independent

Background

The clinical lore is that clomipramine is more effective than SSRIs for OCD, but several analyses question that. Here’s why:

  • Clomipramine has a larger effect size (0.9 vs 0.6), but its trials came first, and may have enrolled a more treatment-responsive group.
  • Clomipramine has more side effects, which may unblind patients to the treatment, exaggerating the benefits.
  • Head-to-head trials show no difference.
  • Meta-analyses that adjust for confounders in the trials show only a marginal or no difference.

On the other hand, it is the most potent in its serotonergic receptor binding, and it did beat fluoxetine in secondary outcomes in a head-to-head trial.

This one takes another look, using the network meta-analytic technique, a ranking system that has its flaws, such as assuming that all trials and all placebo groups are comparable.

The Study
  • 52 double-blind randomized controlled trials (7,316 patients): 43 in adults, 9 in youth.
  • Compared clomipramine, six SSRIs, venlafaxine, and placebo over 8 to 16 weeks.
  • Outcomes were change on the OCD scale (Y-BOCS) and dropout due to side effects.
Results

In adults, clomipramine had the largest effect over placebo (effect size 0.71). The SSRIs effect size ranged from 0.37 (fluoxetine) to 0.63 (fluvoxamine) and performed about the same. In head-to-head trials, clomipramine only beat fluoxetine (and in the original trial, this was on secondary outcomes).

In youth, clomipramine’s edge looked larger (effect size 1.19), but it rested on one trial of 31 patients.

Adults on clomipramine were nearly five times more likely than those on placebo to quit due to side effects, more than on most SSRIs. Escitalopram was the only drug that worked without raising side-effect dropouts.

Venlafaxine did no better than placebo.

SSRI response climbed from 20 to 40 mg fluoxetine-equivalent, with no further gain at 60 mg.

Two large, older trials drove most of clomipramine’s apparent advantage.

Practice Implications
  1. Clomipramine may have an advantage, but it’s not large enough to show up consistently.
  2. In practice, personalizing the medication to one that is tolerable and effective for that patient is more important than finding the most effective serotonergic medication (an elusive goal).
  3. Therapy (exposure and response prevention) is necessary for most patients with OCD.

—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report

What’s Your Take? Share in Comments

Leave a Reply

Your email address will not be published. Required fields are marked *